|
1
|
Taal BG and Visser O: Epidemiology of
neuroendocrine tumors. Neuroendocrinology. 80(Suppl 1): 3–7. 2004.
View Article : Google Scholar
|
|
2
|
Saad MF, Ordonez NG, Rashid RK, Guido JJ,
Hill CS Jr, Hickey RC and Samaan NA: Medullary carcinoma of the
thyroid. A study of the clinical features and prognostic factors in
161 patients. Medicine. 63:319–342. 1984.PubMed/NCBI
|
|
3
|
Vitale G, Caraglia M, Ciccarelli A and
Lupoli G, Abbruzzese A, Tagliaferri P and Lupoli G: Current
approaches and perspectives in the therapy of medullary thyroid
carcinoma. Cancer. 91:1797–1808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eng C and Mulligan LM: Mutations of the
RET proto-oncogene in the multiple endocrine neoplasia type 2
syndromes, related sporadic tumors, and Hirschsprung disease. Hum
Mutat. 9:97–109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Modlin IM, Kidd M, Latich I, Zikusoka MN
and Shapiro MD: Current status of gastrointestinal carcinoids.
Gastroenterology. 128:1717–1751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scheuba C, Kaserer K, Weinhausl A, Pandev
R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA and
Niederle B: Is medullary thyroid cancer predictable? A prospective
study of 86 patients with abnormal pentagastrin tests. Surgery.
126:1089–1095. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Orlandi F, Caraci P, Mussa A, Saggiorata
E, Pancani G and Angeli A: Treatment of medullary thyroid
carcinoma: an update. Endocr Relat Cancer. 8:135–147. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Modlin IM, Latich I, Kidd M, Zikusoka M
and Eick G: Therapeutic options for gastrointestinal carcinoids.
Clin Gastroenterol Hepatol. 4:526–547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li ZX, Sturm S, Stuppner H, Schraml E,
Aguiriano Moser V, Siegl V and Pfragner R: The dichloromethane
fraction of Stemona tuberosae Lour inhibits tumor cell
growth and induces apoptosis of human medullary thyroid carcinoma
cells. Biologics. 1:455–463. 2007.
|
|
10
|
Li ZX, Sturm S, Svejda B, Höger H, Schraml
E, Ingolic E, Siegl V, Stuppner H and Pfragner R: Anticancer
activity of novel extracts from Cautleya gracilis (Smith)
Dandy: Apoptosis in human medullary thyroid carcinoma cells.
Anticancer Res. 28:2705–2714. 2008.PubMed/NCBI
|
|
11
|
Rinner B, Li ZX, Haas H, Siegl V, Sturm S,
Stuppner H and Pfragner R: Antiproliferative effects of Uncaria
tomentosa in human medullary thyroid carcinoma cell. Anticancer
Res. 29:4519–4528. 2009.PubMed/NCBI
|
|
12
|
Nguyen-Pouplin J, Tran Ho, Tran Hu, Phan
TA, Dolecek C, Farrar J, Tran TH, Caron P, Bodo B and Grellier P:
Antimalarial and cytotoxic activities of ethnopharmacologically
selected medicinal plants from South Vietnam. J Ethnopharmacol.
109:417–427. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Strasser M: Phytochemische Untersuchung
von Christia vespertilionis. Diploma thesis. University of
Innsbruck; 2010
|
|
14
|
Pfragner R, Höfler H, Behmel A, Ingolic E
and Walser V: Establishment and characterization of continuous cell
line MTC-SK derived from a human medullary thyroid carcinoma.
Cancer Res. 50:4160–4166. 1990.PubMed/NCBI
|
|
15
|
Pfragner R, Wirnsberger G, Niederle B,
Behmel A, Rinner I, Mandl A, Wawrina F, Luo J-S, Adamiker D, Höger
H, Ingolic E and Schauenstein K: Establishment of a continuous cell
line from a human carcinoid of the small intestine (KRJ-I).
Int J Oncol. 8:513–520. 1996.PubMed/NCBI
|
|
16
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:2002–2007. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Da Violante G, Zerrouk N, Richard I,
Provot G, Chaumeil JC and Arnaud P: Evaluation of the cytotoxicity
of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell
cultures. Biol Pharm Bull. 25:1600–1603. 2002.PubMed/NCBI
|
|
18
|
Li ZD, Liu Y, Liao Y and Zuo GQ: Sorafenib
and octreotide combination therapy can inhibit proliferation of and
induce apoptosis in human hepatoma cells. Zhonghua Gan Zang Bing Za
Zhi. 20:126–130. 2012.(in Chinese).
|
|
19
|
Cao Z, Liao L, Chen X, Lan L, Hu H, Liu Z,
Chen L, Huang S and Du J: Enhancement of antitumor activity of
low-dose 5-fluorouracil by combination with fuzheng-yiliu granules
in hepatoma 22 tumor-bearing mice. Integr Cancer Ther. Jul
12–2012.(Epub ahead of print).
|
|
20
|
Yang KP, Liang YF and Samaan NA: Intrinsic
drug resistance in a human medullary thyroid carcinoma cell line:
association with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res. 11:1065–1068. 1991.PubMed/NCBI
|
|
21
|
Carlomagno F, Salvatore D, Santoro M, de
Franciscis V, Quadro L, Panariello L, Colantuoni V and Fusco A:
Point mutation of the RET protooncogene in the TT human
medullary thyroid carcinoma cell line. Biochem Biophys Res Commun.
207:1022–1028. 1995.PubMed/NCBI
|
|
22
|
Yang YH, Zhao M, Li WM, Chen YY, Kang B
and Lu YY: Expression of programmed cell death 5 gene involves in
regulation of apoptosis in gastric tumor cells. Apoptosis.
11:993–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu G, Wei Y and Kang Y: The multifaceted
role of MTDH/AEG-1 in cancer progression. Clin Cancer Res.
15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Zhang XD, Thompson JF, Screaton G and Hersey P: Progression in
melanoma is associated with decreased expression of death receptors
for tumor necrosis factor-related apoptosis-inducing ligand. Hum
Pathol. 37:1286–1294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas LR, Bender LM, Morgan MJ and
Thorburn A: Extensive regions of the FADD death domain are required
for binding to the TRAIL receptor DR5. Cell Death Differ.
13:160–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sheikh MS, Burns TF, Huang Y, Wu GS,
Amundson S, Brooks KS, Fornace AJ Jr and El-Deiry WS: p53-dependent
and -independent regulation of the death receptor KILLER/DR5 gene
expression in response to genotoxic stress and tumor necrosis
factor alpha. Cancer Res. 58:1593–1598. 1998.PubMed/NCBI
|
|
27
|
Chaudhary PM, Eby M, Jasmin A, Bookwalter
A, Murray J and Hood L: Death receptor 5, a new member of the TNFR
family, and DR4 induce FADD-dependent apoptosis and activate the
NFκB pathway. Immunity. 7:821–830. 1997.PubMed/NCBI
|
